Literature DB >> 9759945

Effect of sucralfate on gastric mucosal inflammatory responses induced by Helicobacter pylori lipopolysaccharide.

B L Slomiany1, J Piotrowski, A Slomiany.   

Abstract

BACKGROUND: Helicobacter pylori lipopolysaccharide is emerging as a primary factor in the bacterium virulence, and its involvement in causing gastric mucosal responses typical of gastritis has recently been shown. In this study we investigated the effect of the antiulcer agent sucralfate on the expression of regulatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and interleukin-4 (IL-4), and epithelial cell apoptosis during H. pylori lipopolysaccharide-induced acute gastritis.
METHODS: The experiments were conducted with rats pretreated intragastrically twice daily for 3 days with sucralfate at 100 mg/kg or the vehicle. The rats were then subjected to intragastric surface epithelial application of H. pylori lipopolysaccharide at 50 microg per animal and maintained on the sucralfate or vehicle regimen for an additional 4 days. The animals were killed 16 h after the last dose, and their gastric mucosal tissue used for histologic assessment, quantitation of TNF-alpha and IL-4 expression, and the assay of epithelial cell apoptosis.
RESULTS: In the absence of sucralfate, H. pylori lipopolysaccharide induced acute mucosal responses characterized by the inflammatory infiltration of the lamina propria, hyperemia, and epithelial hemorrhage. This was accompanied by an 11-fold increase in gastric epithelial cell apoptosis and a 9-fold enhancement of the mucosal expression of TNF-alpha, but the level of IL-4 fell by 15%. Intragastric administration of sucralfate produced a 62% reduction in the extent of mucosal damage caused by H. pylori lipopolysaccharide, a 51% decrease in the mucosal expression of TNF-alpha, and a 7-fold reduction in the extent of epithelial cell apoptosis, whereas the expression of IL-4 increased by 52%.
CONCLUSIONS: Gastric mucosal inflammatory responses to H. pylori lipopolysaccharide are characterized by a massive enhancement of the proinflammatory cytokine TNF-alpha and epithelial cell apoptosis and repression of IL-4. Our data also show that sucralfate is capable of inducing expression of the regulatory cytokine IL-4 and the suppression of apoptotic events triggered in gastric mucosa by the increase in TNF-alpha that is elicited by H. pylori lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9759945     DOI: 10.1080/003655298750026912

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  5 in total

Review 1.  Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives.

Authors:  Suresh P Sulochana; Muzeeb Syed; Devaraj V Chandrasekar; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

2.  Cytotoxicity associated with induction of nitric oxide synthase in rat duodenal epithelial cells in vivo by lipopolysaccharide of Helicobacter pylori: inhibition by superoxide dismutase.

Authors:  D Lamarque; A P Moran; Z Szepes; J C Delchier; B J Whittle
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

3.  Gastritis induced by Helicobacter pylori infection in experimental rats.

Authors:  Mohamed M Elseweidy; Mona M Taha; Nahla N Younis; Khadiga S Ibrahim; Hamdi A Hamouda; Mohamed A Eldosouky; Hala Soliman
Journal:  Dig Dis Sci       Date:  2010-01-22       Impact factor: 3.199

4.  Gastric mucosal inflammatory responses toHelicobacter pylori lipopolysaccharide: suppression of caspase-3 and nitric oxide synthase-2 by omeprazole and sucralfate.

Authors:  B L Slomiany; J Piotrowski; A Slomiany
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

5.  Aegle marmelos fruit extract attenuates Helicobacter pylori Lipopolysaccharide induced oxidative stress in Sprague Dawley rats.

Authors:  Yarasi Gayathri Ramakrishna; Kumarasamy Savithri; Manfred Kist; Sivasitamparam Niranjali Devaraj
Journal:  BMC Complement Altern Med       Date:  2015-10-19       Impact factor: 3.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.